CN113461563A - Nqo1激活型6-重氮基-5-氧代-l-正亮氨酸前药及其制备方法和应用 - Google Patents
Nqo1激活型6-重氮基-5-氧代-l-正亮氨酸前药及其制备方法和应用 Download PDFInfo
- Publication number
- CN113461563A CN113461563A CN202110849576.5A CN202110849576A CN113461563A CN 113461563 A CN113461563 A CN 113461563A CN 202110849576 A CN202110849576 A CN 202110849576A CN 113461563 A CN113461563 A CN 113461563A
- Authority
- CN
- China
- Prior art keywords
- prodrug
- cells
- nqo1
- diazo
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110849576.5A CN113461563B (zh) | 2021-07-27 | 2021-07-27 | Nqo1激活型6-重氮基-5-氧代-l-正亮氨酸前药及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110849576.5A CN113461563B (zh) | 2021-07-27 | 2021-07-27 | Nqo1激活型6-重氮基-5-氧代-l-正亮氨酸前药及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113461563A true CN113461563A (zh) | 2021-10-01 |
CN113461563B CN113461563B (zh) | 2022-05-10 |
Family
ID=77882601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110849576.5A Active CN113461563B (zh) | 2021-07-27 | 2021-07-27 | Nqo1激活型6-重氮基-5-氧代-l-正亮氨酸前药及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113461563B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023202651A1 (en) * | 2022-04-21 | 2023-10-26 | Jacobio Pharmaceuticals Co., Ltd. | Polymorphic forms of glutamine antagonist and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58177934A (ja) * | 1982-04-13 | 1983-10-18 | Takeda Chem Ind Ltd | ベンゾキノン誘導体 |
CN108290827A (zh) * | 2015-07-31 | 2018-07-17 | 约翰霍普金斯大学 | 谷氨酰胺类似物的前药 |
WO2020167831A1 (en) * | 2019-02-11 | 2020-08-20 | Dracen Pharmaceuticals, Inc. | Method of preparing a don prodrug from l-glutamic acid |
WO2020167829A1 (en) * | 2019-02-11 | 2020-08-20 | Dracen Pharmaceuticals, Inc. | Method of preparing a don prodrug from l-pyroglutamic acid |
-
2021
- 2021-07-27 CN CN202110849576.5A patent/CN113461563B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58177934A (ja) * | 1982-04-13 | 1983-10-18 | Takeda Chem Ind Ltd | ベンゾキノン誘導体 |
CN108290827A (zh) * | 2015-07-31 | 2018-07-17 | 约翰霍普金斯大学 | 谷氨酰胺类似物的前药 |
WO2020167831A1 (en) * | 2019-02-11 | 2020-08-20 | Dracen Pharmaceuticals, Inc. | Method of preparing a don prodrug from l-glutamic acid |
WO2020167829A1 (en) * | 2019-02-11 | 2020-08-20 | Dracen Pharmaceuticals, Inc. | Method of preparing a don prodrug from l-pyroglutamic acid |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023202651A1 (en) * | 2022-04-21 | 2023-10-26 | Jacobio Pharmaceuticals Co., Ltd. | Polymorphic forms of glutamine antagonist and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN113461563B (zh) | 2022-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110981870B (zh) | 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途 | |
Yaseen et al. | Pyridazinone substituted benzenesulfonamides as potent carbonic anhydrase inhibitors | |
US11203597B2 (en) | Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing | |
CN107118249B (zh) | 18β-甘草次酸衍生物及其应用 | |
CA3135740A1 (en) | Cancer treatments targeting cancer stem cells | |
US10561681B2 (en) | Antimetastatic 2H-selenopheno[3,2-h]chromenes, synthesis thereof, and methods of using same agents | |
WO2023142518A1 (zh) | 羟基萘酮-苯硼酸类化合物、制备方法和用途 | |
CN113461563B (zh) | Nqo1激活型6-重氮基-5-氧代-l-正亮氨酸前药及其制备方法和应用 | |
KR102434764B1 (ko) | 간 전송 항바이러스 전구체 약물 뉴클레오시드 시클로 포스페이트 에스테르 화합물 및 응용 | |
CN112341493A (zh) | 一种基于三苯基膦修饰的线粒体靶向褪黑素及其制备方法和应用 | |
CN109942630B (zh) | 基于柳胺酚和紫檀芪的天然活性分子偶联化合物及其用途 | |
Harikandei et al. | Synthesis, in-vitro antiprotozoal activity and molecular docking study of isothiocyanate derivatives | |
KR101975299B1 (ko) | 인돌아세트산의 코어구조를 함유하는 화합물 및 그의 용도 | |
EP4039674A1 (en) | Sulfo-substituted biaryl compound or salt thereof, preparation method therefor, and use thereof | |
Perez et al. | Synthesis and biological evaluation of new securinine analogues as potential anticancer agents | |
CN104327097A (zh) | 雷帕霉素的三氮唑衍生物和用途 | |
US6566341B1 (en) | Derivative of isoindigo, indigo and indirubin for the treatment of cancer | |
CN111417620B (zh) | 肌酸前药、其组合物以及使用方法 | |
TW201922690A (zh) | 環-amp反應元素結合蛋白的抑制劑 | |
WO2013123745A1 (zh) | 齐多夫定喹啉共轭化合物及其制备方法和抗肝癌之应用 | |
CN115385819A (zh) | 一种迷迭香酸生物电子等排体及其制备方法和应用 | |
Dupommier et al. | New desulfured troglitazone derivatives: improved synthesis and biological evaluation | |
EP4043467A1 (en) | Class of functional molecules targeting proteolysis pathways, preparation and application thereof | |
US9499552B2 (en) | Pyrazolo[1,5-A]pyrimidine derivative and use of anti-tumor thereof | |
CN104530081A (zh) | 雷帕霉素的氮杂环衍生物和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20211001 Assignee: Nanjing Baize Pharmaceutical Technology Co.,Ltd. Assignor: CHINA PHARMACEUTICAL University Contract record no.: X2023320000091 Denomination of invention: NQO1-activated 6-diazo-5-oxo-L-leucine prodrug and its preparation method and application Granted publication date: 20220510 License type: Common License Record date: 20230208 Application publication date: 20211001 Assignee: CHANGZHOU SIYAO PHARMACY Co.,Ltd. Assignor: CHINA PHARMACEUTICAL University Contract record no.: X2023320000090 Denomination of invention: NQO1-activated 6-diazo-5-oxo-L-leucine prodrug and its preparation method and application Granted publication date: 20220510 License type: Common License Record date: 20230208 |